Mandated Part D Rebates Would Not Lead To Higher Premiums, Cost Shifts, MedPAC Commissioner Argues
This article was originally published in The Pink Sheet Daily
In an online Health Affairs article, MedPAC commissioner Jack Hoadley and co-author Richard Frank rebut arguments against mandatory rebates on Medicare Part D drugs.
You may also be interested in...
Some patient groups ask Congress not to consider Medicaid-style rebates for dual-eligibles and low-income subsidy recipients in Medicare Part D; 72% of office-based physicians are using electronic health records; disparities in Medicaid EHR adoption, based on allocation of incentive payments, mirror those found in Medicare EHR adoption.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.